Page 28 - Central Drug Authority Annual Report 2021
P. 28
6. MONITORING AND EVALUATION
7KH &'$ %XVLQHVV 3ODQ UHTXLUHG WKDW DFKLHYHPHQWV EH ,Q VXSSRUW RI WKH UHFRPPHQGDWLRQV DQG DW WKH UHTXHVW RI WKH
UHSRUWHG LQ WHUPV RI WKH UHVXOWV DWWDLQHG 7KLV DOVR UHTXLUHG WKHQ 0LQLVWHU D VWXG\ ZDV PDGH E\ WKH &'$ RI VLPLODU RUJDQ-
WKDW WKH UHSRUWV RI WKH 'HSDUWPHQWV DQG 3URYLQFHV EH LVDWLRQV LQ VHOHFWHG RWKHU FRXQWULHV WR HQDEOH WKH 0LQLVWHU WR
FRPSOHWHG LQ WHUPV RI WKH UHVXOWV DFKLHYHG 0XFK WLPH DQG GHFLGH RQ WKH UHFRPPHQGDWLRQV RI WKH FRQVXOWDQWV 7LWOHG
HIIRUW ZHUH H[SHQGHG RQ WKLV UHTXLUHPHQW EXW LQ WKH PDLQ Ȣ$Q RYHUYLHZ RI VHOHFWHG DQWL GUXJ RUJDQLVDWLRQV LQ VHOHFWHG
UHSRUWV ZHUH FRPSOHWHG LQ WHUPV RI WKH DFWLYLWLHV FDUULHG RXW FRXQWULHVȣ LW ZDV VXEPLWWHG LQ VXSSRUW RI WKH &'$ȠV UHFRP-
E\ RUJDQLVDWLRQV PDGH XS RI WKH VXSSRUWLQJ VWUXFWXUHV D PHQGDWLRQV FRQFHUQLQJ WKH SURSRVHG &'$ VWUXFWXUH
VLWXDWLRQ WKDW PDGH UHSRUWLQJ WR WKH &DELQHW GLIˉFXOW WR
DFKLHYH IRU WKH &'$ ,Q WKH UHSRUWLQJ \HDU WKH *RYHUQPHQW LQWURGXFHG
D PRQLWRULQJ DQG HYDOXDWLRQ SROLF\ WKDW VXSSRUWV WKH
7KH UG &'$ LV LQ WKH ZRUGV RI WKH SUHYLRXV 0LQLVWHU RI FRQFHSW RI UHSRUWLQJ LQ WHUPV RI UHVXOWV DQG WKH 1'03
6RFLDO 'HYHORSPHQW ȟ$Q $XWKRULW\ ZLWKRXW DXWKRULW\Ƞ 7KH KDV EHHQ FRPSLOHG ZLWK WKDW LQ PLQG 7KH SROLF\
RUJDQLVDWLRQDO UHODWLRQVKLS EHWZHHQ WKH &'$ DQG WKH LV FRQWDLQHG LQ WKH 3XEOLF 6HUYLFH &RPPLVVLRQ SXEOLFDWLRQ
QDWLRQDO 'HSDUWPHQW RI 6RFLDO 'HYHORSPHQW ZKLFK LQ WHUPV ȟ%DVLF &RQFHSWV LQ 0RQLWRULQJ DQG (YDOXDWLRQȠ RI )HEUXDU\
RI WKH $FW UHSRUWV WR WKH &'$ LV DV H[SUHVVHG E\ WKH 'LUHF-
WRU *HQHUDO RI WKDW 'HSDUWPHQW ȟLQFHVWXRXVȠ EHFDXVH RI WKH
H[FHSWLRQDO FORVHQHVV WKDW PDNHV WKH LQWHUUHODWLRQV 7KH DGRSWLRQ RI WKLV DSSURDFK UHTXLUHV WKDW WKH &'$ GHVLJQ
EHWZHHQ WKH WZR XQSURGXFWLYH DQG XQ VHHPLQJO\ PRQLWRULQJ IUDPHZRUNV DQG HYDOXDWLRQ TXHVWLRQV L H
PHDVXULQJ LQVWUXPHQWV 7KHVH PHDVXULQJ LQVWUXPHQWV ZRXOG
,Q VXSSRUW RI WKH VWDWHPHQW E\ WKH 0LQLVWHU LW VKRXOG EH WKHQ EH XVHG WR DVVHVV DQG UHSRUW RQ WKH DFKLHYHPHQW RI
UHPHPEHUHG WKDW WKH &'$ LV LQ HVVHQFH D SDUW WLPH ERG\ ,PSDFW 2XWFRPHV DQG DFWLYLWLHV FRQWDLQHG LQ DQG GHULYHG
ZLWK WKH PDMRULW\ RI LWV PHPEHUV IXQFWLRQLQJ IXOO WLPH LQ IURP WKH 1'03
RUJDQLVDWLRQV QRW UHODWHG WR WKH &'$ :KLOVW WKLV LV QRUPDO LQ
PDQ\ %RDUGV WKH ORFDWLRQ RI WKH &'$ DQG LWV UHODWLRQVKLS LV 7KH 1'03 KDV EHHQ IUDPHG LQ WHUPV RI ,PSDFW
VWUHQXRXV DV LW LV DOVR SHUFHLYHG DV WKH VWHS FKLOG RI WKH 2XWFRPHV DQG 2XWSXWV DQG FRQWDLQV VRPH ,QSXW GHWDLOV 1R
GHSDUWPHQW ZKLFK PXVW DQVZHU WR WKH GHSDUWPHQW DQG EH PHDVXULQJ LQVWUXPHQWV KDYH KRZHYHU EHHQ GHYHORSHG WR
VXEMHFW WR LWV KLHUDUFKLFDO DUUDQJHPHQWV GDWH
$ VWXG\ ZDV FRPPLVVLRQHG E\ WKH 1DWLRQDO 'HSDUWPHQW RI
6RFLDO 'HYHORSPHQW $ FRQVXOWDQW ERG\ 'HORLWWH DQG
7RXFK« FRQGXFWHG WKH VWXG\ DQG PDGH FHUWDLQ UHFRPPHQ-
GDWLRQV FRQFHUQLQJ WKH UHYLHZLQJ RI WKH &'$ DQG LWV UHVWUXF-
WXULQJ VR DV WR HQDEOH LW WR SXUVXH LWV PDQGDWH
26 Annual Report 2020/2021 Central Drug Authority
